Allogene Therapeutics Stock Price, News & Analysis

Allogene Therapeutics (ALLO) announced the resumption of its AlloCAR T clinical studies following the lifting of a clinical hold by the FDA in January 2022. The company has initiated patient enrollment for multiple trials, including the pivotal Phase 2 ALPHA2 trial for ALLO-501A targeting relapsed/refractory large B cell lymphoma. With $810 million available at the end of 2021, and a reported net loss of $257 million, Allogene anticipates 2022 operating expenses between $360 million and $390 million. Future updates are expected during a conference call scheduled today.

Allogene Therapeutics (Nasdaq: ALLO) will announce its fourth quarter and year-end 2021 financial results on February 23, 2022, after market close. A live audio webcast and conference call are scheduled for 2:00 PM PT/5:00 PM ET. The announcement highlights Allogene's work in developing allogeneic CAR T cell therapies, aiming for reliable, scalable treatments for cancer. The company emphasizes its commitment to innovation in cell therapy.

Allogene Therapeutics (Nasdaq: ALLO) has announced participation in four virtual investor conferences focused on oncology. These include the B. Riley Virtual Oncology Investor Conference on January 27, 2022, the 4th Annual Guggenheim Oncology Day on February 9, 2022, the Cowen 42nd Annual Health Care Conference on March 7, 2022, and the Oppenheimer's 32nd Annual Healthcare Conference on March 15, 2022. Webcasts will be available on the company's website, allowing for replays for approximately 30 days.

Allogene Therapeutics (Nasdaq: ALLO) has entered an exclusive global collaboration with Antion Biosciences to utilize Antion's miCAR technology for advancing allogeneic CAR T (AlloCAR T™) therapy. This partnership aims to enhance multiplex gene silencing capabilities, with potential applications in immune evasion strategies. Allogene will provide an upfront cash payment and a preferred equity investment, alongside developmental and commercial milestone payments, and single-digit royalties on product sales. The collaboration seeks to accelerate Allogene's research in cell therapies designed to treat cancer.

Allogene Therapeutics announced the removal of a clinical hold by the FDA on its AlloCAR T clinical trials following an investigation. The investigation confirmed the chromosomal abnormality found in a patient was unrelated to Allogene's manufacturing process or TALEN gene editing. Clinical trials across the AlloCAR T platform are set to resume, with the pivotal Phase 2 trial of ALLO-501A in relapsed/refractory large B-cell lymphoma expected to start in mid-2022, pending FDA discussions. The company expresses gratitude for the collaboration with the FDA and clinical investigators.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced that its President and CEO, David Chang, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 12:45 p.m. PT. This presentation focuses on the development of allogeneic CAR T therapies for cancer by Allogene, a pioneering biotechnology firm based in South San Francisco. A live webcast will be available on the company's website, with a replay accessible for 30 days post-event. For further details, visit www.allogene.com.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced a lease agreement to expand its headquarters in South San Francisco, effective April 1, 2022. The new facility will add 47,566 square feet of office and laboratory space, increasing total occupancy to over 100,000 square feet. This expansion supports Allogene's research capabilities and clinical development of AlloCAR T™ therapies aimed at treating hematologic cancers and solid tumors. The company has also developed a cutting-edge manufacturing facility in Newark, California.

Allogene Therapeutics (NASDAQ: ALLO) announced promising results from the Phase 1 UNIVERSAL trial of ALLO-715, the first allogeneic anti-BCMA CAR T therapy for multiple myeloma demonstrating substantial safety and efficacy. The trial achieved a 71% overall response rate (ORR), with 46% achieving a very good partial response (VGPR) or better. Notably, no cases of graft-versus-host disease were reported. The study enables rapid therapy initiation, with a median treatment start time of five days. ALLO-715 received RMAT designation from the FDA, reinforcing its potential in treating relapsed/refractory myeloma.